Breast cancer metastatic
Not recruitingStudy of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease
Study of fulvestrant and palbociclib combination for postmenopausal women with hormone receptor-positive metastatic breast cancer who completed 5 years of hormone therapy or have new metastatic disease
- Disease:Breast cancer metastatic
- Substances:FulvestrantPalbociclib
Ireland- Participants:18–64 years · 65+ years
- Substances:Fulvestrant
- Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer De Mama





